{"id":"metformin-1500mg-qd","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3-5","effect":"Metallic taste"},{"rate":"10-30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin decreases gluconeogenesis in the liver and enhances peripheral glucose uptake and utilization, primarily through AMPK activation. It also improves insulin sensitivity and may have modest effects on gastrointestinal glucose absorption. The drug does not stimulate insulin secretion, making it weight-neutral and suitable for use across a broad range of glucose levels.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:55.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05952882","phase":"PHASE3","title":"Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility","status":"UNKNOWN","sponsor":"Mỹ Đức Hospital","startDate":"2023-11-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":188},{"nctId":"NCT02947620","phase":"PHASE3","title":"Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2015-08","conditions":"Type II Diabetes, Dyslipidemia","enrollment":185},{"nctId":"NCT02586129","phase":"PHASE3","title":"Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-11-04","conditions":"Dyslipidemia, Type II Diabetes","enrollment":249}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin 1500mg, QD","genericName":"Metformin 1500mg, QD","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}